Valuation: hVIVO plc

Market Cap 40.53M 53.45M 47.91M 44.63M 76.06M 5.09B 76.65M 536M 209M 2.64B 201M 196M 8.46B P/E 2026 *
-5.88x
P/E 2027 * -28.1x
Enterprise Value 45.08M 59.45M 53.28M 49.64M 84.6M 5.66B 85.25M 596M 233M 2.94B 223M 218M 9.41B EV / Sales 2026 *
0.96x
EV / Sales 2027 * 0.72x
Free-Float
96.89%
Yield 2026 *
-
Yield 2027 * 1.32%
1 day+27.29%
6 months+27.29%
Current year-54.33%
Current year 0.09
Extreme 0.0861
0.11
1 year 0.09
Extreme 0.0861
0.11
3 years 0.09
Extreme 0.0861
0.37
5 years 0.09
Extreme 0.0861
0.37
10 years 0
Extreme 0.001929
0.56
Manager TitleAgeSince
Chief Executive Officer 57 2022-02-23
Corporate Officer/Principal 39 2017-06-30
Director of Finance/CFO 65 2026-09-29
Director TitleAgeSince
Director/Board Member 57 2021-10-12
Chairman 59 2025-08-31
Director/Board Member - 2026-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+27.29%-.--% - - 53.7M
-2.01%-7.86%+54.60%+70.97% 70.44B
+3.84%-10.61%+6.97%+57.43% 50.31B
+3.35%+1.60%+10.58%+40.01% 47.51B
+0.51%+0.78%+28.58%+31.43% 42.91B
+2.70%-3.18%+296.96%+547.01% 40.39B
+0.69%-3.11%+7.48%+96.59% 39.69B
+0.06%-1.43%+10.47%+43.27% 30.59B
-2.95%-14.09%+37.94%+1.30% 26.8B
-0.39%-7.39%-13.33%-14.40% 22.36B
Average +3.31%-5.58%+48.92%+97.07% 41.22B
Weighted average by Cap. +0.77%-5.44%+51.90%+102.70%

Financials

2026 *2027 *
Net sales 47.02M 62.01M 55.58M 51.78M 88.24M 5.9B 88.92M 622M 243M 3.06B 233M 228M 9.81B 56.9M 75.03M 67.25M 62.65M 107M 7.14B 108M 752M 294M 3.71B 282M 276M 11.87B
Net income -6.47M -8.54M -7.65M -7.13M -12.15M -812M -12.24M -85.58M -33.43M -422M -32.03M -31.35M -1.35B -1.89M -2.49M -2.23M -2.08M -3.55M -237M -3.58M -25M -9.77M -123M -9.36M -9.16M -395M
Net Debt 4.55M 6M 5.38M 5.01M 8.54M 571M 8.6M 60.15M 23.5M 296M 22.51M 22.04M 949M 255K 336K 301K 280K 478K 31.97M 482K 3.37M 1.32M 16.6M 1.26M 1.23M 53.15M
Projected Income Statement - Annual - hVIVO plc
Logo hVIVO plc
hVIVO plc is a United Kingdom-based purpose-built, full-service international clinical development partner and engaged in human challenge trials serving biopharma companies. The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first in human studies, Phase II patient trials and specialist laboratory services, delivered through a participant database, wholly owned sites and laboratories across the UK and Germany. The Company offers integrated service lines which include consulting, clinical trials, human challenge trials, and laboratories. Its consulting provides preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation. The Company is also focused on Phase I/II clinical studies, particularly in dermatology and women's health.
Employees
376
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - hVIVO plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.0590GBP
Average target price
0.1550GBP
Spread / Average Target
+162.71%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - hVIVO plc